U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.54%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.41%)
     
  • BTC-USD

    19,141.77
    -469.02 (-2.39%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Eurobio Scientific launches 2 new proprietary tests for the diagnosis of new variants of SARS-CoV-2 and Monkeypox

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Eurobio Scientific
Eurobio Scientific

Eurobio Scientific launches 2 new proprietary tests for the diagnosis of new variants of SARS-CoV-2 and Monkeypox

  • EBX048 : a routine COVID screening test that simultaneously detects and identifies the presence of Omicron BA.1, Omicron BA.2 and Omicron BA.4/BA.5

  • EBX060 : routine viral test for the differential diagnosis of simian pox, varicella and measles viruses

  • First French test for screening of Omicron BA.4/BA.5 variants or of the 3 viruses including simian pox, requiring only one reaction and delivering a result in 45 minutes

Paris, le June 20 2022, 5:45 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in specialty in vitro medical diagnostics, announces today the availability of two new proprietary tests: EBX 048, Eurobioplex SARS-CoV-2 Fast-SVT (Screening and VOC1 Typing), developed́ specifically for routine screening of COVID-19 and identification of current variants including BA.4 /BA.5, and EBX 060, Eurobioplex SARS-CoV-2 Monkeypox Screening Test (hMPXV, VZV, Measles), developed́ specifically for routine screening of simian pox, varicella and measles viruses.

The proprietary EBX SARS-CoV-2 Fast-SVT is a real-time polymerase chain reaction (RT-PCR2) assay that, in a single test, identifies the presence of the SARS-CoV-2 virus and detects the K417N (Omicron variant BA.x sublineage screening), S:V213G (Omicron variant BA.2 and BA.4/BA.5 sublineage screening) and L452R (BA.4/BA.5 sublineage screening in the presence of the S:V213G mutation) mutations in a qualitative manner. The presence of the 3 mutations thus allows the BA.4/BA.5 sublineages to be differentiated from other sublineages of the Omicron variant.

The proprietary EBX Monkeypox Screening Test (hMPXV, VZV, Measles) is a real-time polymerase chain reaction (RT-PCR2) test that, in a single test, identifies the presence of 3 viruses responsible for a clinical picture characterized in particular by a widespread rash.

These new tests, designed and developed by Eurobio Scientific's R&D department, are produced in-house, in its premises in Les Ulis - France and follows the ISO 13485 regulatory process. It is available in several versions allowing 25, 50, 100, 200 or 600 determinations to be performed simultaneously.

EBX SARS-CoV-2 Fast-SVT and EBX Monkeypox Screening Test (hMPXV, VZV, Measles) are immediately available for hospital and private laboratories, both in France and internationally in their CE-IVD and RUO versions, respectively.

In the area of rapid antigenic tests, Eurobio Scientific has also validated the efficacy of its proprietary EBS-1001 test for the detection of BA.4/BA.5 sub-variants.

With fully internalized R&D and production capabilities and appropriate regulatory expertise, Eurobio Scientific is once again demonstrating its ability to provide the market with tools to monitor the epidemiological evolution of all infectious diseases as closely as possible.

Next financial meeting
2022 first-half revenues: July 25, 2020

Disclaimer
This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, profitability or events to differ materially from those anticipated. In addition, Eurobio Scientific, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications. Such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 164 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.
For more information, please visit : www.eurobio-scientific.com
The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

1 VOC : Variant of Concern
2 The "Polymerase Chain Reaction" (PCR) is a method based on the selective multiplication of target DNA sequences, which makes it possible to detect specific DNA sequences present in a product.

Attachment